Navigation Links
Snoasis Medical Initiates Distribution in Japan Through Hausten Healthcare
Date:7/27/2012

DENVER, July 27, 2012 /PRNewswire-iReach/ -- Snoasis Medical, Inc. formally announces the signing of a distribution agreement with Hausten Healthcare, LLC (Honolulu, HI), whereby Hausten Healthcare will distribute BioXclude™ in Japan.  While BioXclude is not approved for use by the Japanese Ministry of Health and Welfare, clinicians may legally import unapproved foreign medical products for treatment of patients in accordance with the Pharmaceutical Affairs Law. 

Hausten Healthcare is expected to begin distribution activities this coming fall.  Highly proficient in managing this unique regulatory landscape, Hausten Healthcare works in conjunction with Japanese clinicians to easily and efficiently navigate the importation process.  According to Robert Tofe, president and founder of Snoasis Medical, "we are currently seeking regulatory approval in Taiwan and South Korea, and are actively working to set up distribution in China.  Our relationship with Hausten allows access to Japan, one of the largest dental markets in the world, and punctuates our efforts to set up distribution throughout East Asia"

Amnion-chorion tissue is often referred to as the amniotic sac, the part of the placenta that encloses and protects the unborn baby through term.  This tissue is considered immunoprivileged, possesses anti-bacterial and anti-microbial properties, reduces inflammation at the wound site, and provides a protein-enriched matrix to naturally facilitate epithelialization and improve overall wound healing.  These attributes provide BioXclude with many benefits over traditional barrier membrane products used by dental professionals in guided bone and tissue regeneration procedures.

Founded in 2007, Snoasis Medical is focused on the development and commercialization of regenerative tissue and medical device products for use in dental surgery.  In 2008, Snoasis obtained the exclusive license and worldwide distribution rights to all current and future placental tissue products processed by Surgical Biologics, A MiMedx Group Company (Kennesaw, GA) for use in dentistry.  Snoasis Medical initiated commercial distribution of BioXclude in the United States in March 2010 and in Canada in September 2010.  For additional information, please visit www.SnoasisMedical.com.

Hausten Healthcare, LLC is a newly formed entity focused on providing Japanese dental clinicians, institutions and patients the best possible tissue regenerative options, some of which are not currently approved by the Japanese Ministry of Health and Welfare.  Created in June 2012, Hausten Healthcare was spun out of RHC Corporation, a company focused on providing Japanese physicians and medical institutions with a greater range of medical treatment options.  

Media Contact: Eric Frank Snoasis Medical, 303-242-8075, efrank@snoasismedical.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Snoasis Medical
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Roche NimbleGen and BGI Develop Advanced MHC Region Capture Technology for Human Disease and Biomedical Research
2. DiaTech Life Sciences Announces Medical Advisory Board
3. Van Andel Institute Partners with UNCF to Recruit Students to Biomedical Research Careers
4. Breaking Study: ICU Medicals Tego® Needlefree Connector Proves More Cost Effective Than Traditional Central Venous Catheter Locks
5. China Sky One Medical to Jointly Launch Adult Stem Cell Research Enterprise
6. Varian Medical Systems Schedules First Quarter FY2012 News Release and Conference Call
7. HealthCare Institute of New Jersey Releases 2011 Biopharmaceutical and Medical Technology Economic Impact Data
8. Saladax Biomedical, Inc. to Present at Biotech Showcase™ 2012
9. Live Press Briefing on Findings of Biomedical Industry CEO Survey
10. Saladax Biomedical, Inc. Issued Six Patents Containing Broad Claims in the Immunoassay Space
11. Scott Brooks Joins Regenesis Biomedical as Chief Operating Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Raleigh, NC (PRWEB) , ... June 27, 2016 ... ... a mission to bring innovative medical technologies, services and solutions to the healthcare ... development and implementation of various distribution, manufacturing, sales and marketing strategies that are ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)...   Boston Biomedical , an industry leader ... target cancer stemness pathways, announced that its lead ... Designation from the U.S. Food and Drug Administration ... gastroesophageal junction (GEJ) cancer. Napabucasin is an orally ... stemness pathways by targeting STAT3, and is currently ...
(Date:6/23/2016)... Cancer Foundation (PCF) is pleased to announce 24 new Young Investigator (YI) ... of the Class of 2016 were selected from a pool of 128 applicants ... the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:4/26/2016)... LONDON , April 26, 2016 /PRNewswire/ ... Systems, a product subsidiary of Infosys (NYSE: ... partnership to integrate the Onegini mobile security platform ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration ... security to access and transact across channels. Using ...
(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys has ... CEO, Barrett Bready , M.D., who returned to ... the original technical leadership team, including Chief Technology Officer, ... Product Development, Steve Nurnberg and Vice President of Software ... the company. Dr. Bready served as CEO ...
Breaking Biology News(10 mins):